Dr. Collet’s tenure comes at a pivotal moment when non-invasive cardiovascular imaging modalities such as coronary computed tomography angiography (CCTA) are redefining diagnostic paradigms. With his expertise, CRF® aims to harness these advances to improve patient stratification and outcomes in coronary artery disease. His leadership will be integral in bridging the gap between cutting-edge imaging techniques and the nuanced understanding of coronary physiology, fostering an environment where translational science accelerates therapeutic innovation.

The appointment reflects CRF®’s commitment to elevating the scientific rigor and clinical impact of its cardiovascular imaging and physiology programs. Dr. Juan F. Granada, President and CEO of CRF®, emphasized the transformative potential of Dr. Collet’s arrival, highlighting how his knowledge of coronary CT technology embodies the future of cardiovascular diagnostics. Dr. Granada underlined the strategic importance of embedding advanced imaging within CRF®’s multifaceted approach to cardiovascular care and research.

At the core of Dr. Collet’s vision is the expansion of CRF®’s imaging portfolio through the introduction of novel coronary and endovascular services. Alexandra Popma, MD, Executive Director of CRF®’s Clinical Trials Center, expressed enthusiasm for the innovative trajectory Dr. Collet will foster. She noted that his combined clinical acumen and scientific leadership are essential for refining imaging capabilities, which are critical for elucidating cardiovascular pathophysiology and enhancing precision medicine strategies.

Dr. Collet’s distinguished background encompasses more than 300 peer-reviewed publications, reflecting his prolific contribution to interventional cardiology, vascular imaging, and translational research. His recent leadership at the Cardiovascular Center OLV Aalst’s catheterization laboratory in Belgium underscored his expertise in applying physiological measurements alongside imaging data to complex coronary artery disease cases. This dual focus on anatomy and physiology is pivotal in advancing personalized treatment approaches.

His educational journey spans multiple continents and specialties, with foundational medical training at the Dante Pazzanese Institute of Cardiology in São Paulo and advanced postgraduate study in cardiac computed tomography angiography at Holy Cross Hospital in Florida. Crucially, Dr. Collet earned a PhD from the University of Amsterdam with research concentrated on the integration of coronary imaging and physiology—a specialty that positions him uniquely to spearhead translational efforts at CRF®.

The integration of coronary CT imaging with physiological measurements like fractional flow reserve (FFR) represents a transformational approach in cardiovascular medicine. By combining anatomical and functional assessments, clinicians can more precisely stratify risk and tailor interventional strategies. Dr. Collet’s expertise in deploying these hybrid modalities will likely accelerate the adoption of evidence-based, minimally invasive diagnostics that reduce procedural complications and improve long-term outcomes.

Innovation within CRF® under Dr. Collet’s direction will not be limited to technological deployment. He advocates for the creation of multidisciplinary platforms that unify translational science, biomedical engineering, and clinical practice. Such platforms are designed to facilitate rapid bench-to-bedside translation of discoveries, integrating artificial intelligence and machine learning to further refine diagnostic precision and predict therapeutic responses.

Dr. Collet’s vision extends to education, ensuring that CRF® remains at the forefront of training healthcare professionals globally. By enhancing curriculum content with the latest imaging and physiology techniques, CRF® aims to cultivate a new generation of cardiologists skilled in interpreting complex diagnostic data and implementing personalized therapies. This educational mission aligns with the foundation’s broader goal of disseminating evidence-based knowledge to improve survival rates and quality of life for patients worldwide.

The synergy between imaging modalities, physiological assessments, and translational therapeutics represents a frontier with immense potential. By uniting these disciplines under Dr. Collet’s leadership, CRF® endeavours to catalyze innovation, foster collaborative research networks, and promote clinical trials that validate new diagnostic and therapeutic strategies. These efforts will ultimately lead to more nuanced and effective management of cardiovascular diseases, including ischemic heart disease and heart failure.

Dr. Collet’s appointment signals a commitment to advancing the cardiovascular field through integrative approaches that leverage technology and clinical insight. As cardiovascular diseases remain a leading cause of morbidity and mortality globally, breakthroughs in imaging and physiology are essential to meet the challenges of early detection and treatment optimization. CRF®’s leadership in this arena is expected to have far-reaching impact, influencing practice guidelines and elevating standards of care worldwide.

Expressing his enthusiasm, Dr. Collet stated, “Joining CRF® allows me to contribute to a mission grounded in innovation, science, and education. We stand on the cusp of transformative change in cardiovascular medicine, driven by imaging and translational research. Together, we will expand our coronary and endovascular services, develop new diagnostic platforms, and foster personalized care paradigms that improve patient outcomes on a global scale.” His appointment exemplifies CRF®’s forward-looking strategy to harness expertise and technology for the betterment of cardiovascular health internationally.

Subject of Research: Cardiovascular Imaging, Coronary CT Angiography, and Translational Therapeutics in Coronary Artery Disease

Article Title: Renowned Cardiologist Dr. Carlos Collet Appointed Director of Cardiovascular Imaging and Translational Therapeutics at CRF®

News Publication Date: September 9, 2025

Web References:
https://mediasvc.eurekalert.org/Api/v1/Multimedia/028f5ce5-58eb-4308-9387-cd55c33520c5/Rendition/low-res/Content/Public

Image Credits: Cardiovascular Research Foundation

Keywords: Cardiovascular Imaging, Coronary CT Angiography, Interventional Cardiology, Translational Therapeutics, Coronary Physiology, Cardiovascular Disease, Cardiovascular Research Foundation, Personalized Cardiovascular Care, Coronary Artery Disease, Cardiac Computed Tomography, Fractional Flow Reserve, Cardiovascular Innovation

SCAI Scientific Sessions 2025 distinguishes itself with an extensive program featuring over 500 expert faculty members, 700 poster presentations, and 86 oral abstracts, highlighted by more than 30 live case demonstrations. This comprehensive setup is designed to foster dynamic dialogue among clinicians, researchers, and innovators, driving forward evidence-based approaches in interventional cardiology. Core sessions will feature breakthroughs in diagnostics, therapeutic interventions, and utilize cutting-edge technology to refine cardiovascular patient management across diverse populations.

The event will prominently feature discussions on Percutaneous Coronary Intervention (PCI), a cornerstone procedure in revascularization therapies. PCI, a catheter-based technique aimed at relieving artery blockages within the coronary circulation, is performed nearly one million times annually in the United States alone. Presentations will introduce novel clinical data from the FAVOR III trial, which compares Quantitative Flow Ratio (QFR) and angiography for physiological guidance in PCI. These findings are expected to refine risk stratification techniques and optimize procedural outcomes, potentially reshaping clinical guidelines within cardiology practice.

Occupational safety in the catheterization laboratory will also be a crucial topic at the meeting. Traditional lead aprons, worn to shield operators from ionizing radiation, can inadvertently contribute to musculoskeletal injuries, particularly chronic back pain. Presentations will reveal research from the ERGO-CATH Study evaluating innovative lead-less or reduced-lead protective solutions. These advancements aim to enhance operator well-being while maintaining radiation safety, a significant development considering the demanding physical environment of interventional cardiology suites.

Transcatheter Aortic Valve Replacement (TAVR), an increasingly adopted minimally invasive alternative to surgical valve replacement, will receive considerable focus. As a therapeutic option for aortic stenosis, TAVR helps alleviate symptoms such as dyspnea and angina by implanting an artificial valve via catheterization. Recent data highlight over 100,000 TAVR procedures performed in the U.S. in 2023 alone. Sessions will explore age-related effects on procedural timing, antiplatelet therapy post-TAVR, and gender-based disparities in prosthesis-patient mismatch, providing granular insight into patient-centric care optimization and procedural efficacy.

A highlight of this year’s conference is the integration of artificial intelligence (AI) and machine learning (ML) within interventional cardiology. These technologies promise to elevate diagnostic accuracy, procedural planning, and post-intervention monitoring through data-driven decision support systems. Attendees will be introduced to early adoption experiences, algorithm validation studies, and AI-powered imaging modalities, all of which signify a monumental shift toward precision medicine in cardiovascular interventions.

The well-being of the cardiovascular healthcare team also takes center stage, reflecting a growing awareness of occupational stress, radiation exposure, and ergonomic challenges faced daily by clinicians. Program elements dedicated to mental health support, radiation safety, and cath lab ergonomics underscore SCAI’s commitment to sustaining a healthy workforce capable of delivering high-quality patient care under demanding conditions.

Importantly, the Scientific Sessions will offer immersive, hands-on learning labs, live case transmissions, and interactive workshops. These educational opportunities provide attendees with practical skills in complex procedures, real-time problem solving, and navigation through evolving clinical protocols. By reinforcing the connection between research findings and clinical application, SCAI aims to accelerate knowledge transfer and enhance patient outcomes internationally.

The conference also underscores the significance of global collaboration. With expanded international participation, this year’s agenda reflects a concerted effort to harmonize standards and share innovations across borders. Such synergy is essential given the worldwide prevalence of cardiovascular diseases and the need for adaptive solutions that are sensitive to diverse healthcare systems and patient demographics.

SCAI President James B. Hermiller, MD, MSCAI, emphasizes that the momentum captured in this edition of Scientific Sessions is unparalleled, fueled by record abstract submissions and an agenda that bridges clinical care, innovation, and career development. The breadth of the program ensures relevance for cardiologists, research scientists, educators, and trainees alike, ultimately advancing the collective mission to reduce the global burden of cardiovascular disease.

In addition to the technical content, attendees and followers are encouraged to engage with real-time updates and discussions through social media channels using #SCAI2025. This digital presence extends the reach of the conference, fostering continuous knowledge exchange beyond the physical venue. Interviews with key opinion leaders, early access to research abstracts, and expert commentary will enhance the conference’s impact and visibility throughout the cardiovascular community.

The SCAI Scientific Sessions continue to affirm the Society’s role as a leading advocate and educator within invasive and interventional cardiology. Established in 1978, SCAI has grown into a global community of over 5,000 members committed to professional excellence, innovation, and high standards of patient care. The 2025 Scientific Sessions epitomize this mission, delivering a rigorous, forward-thinking forum that harnesses the latest science to shape the future of cardiovascular treatment worldwide.

Subject of Research: Advances in Interventional Cardiology and Endovascular Medicine
Article Title: SCAI Scientific Sessions 2025: Pioneering Innovations in Cardiovascular Care and Operator Safety
News Publication Date: Not specified
Web References:

• https://scai.org/scai-2025-scientific-sessions
• https://scai.org/
  Image Credits: Society for Cardiovascular Angiography & Interventions
  Keywords: Clinical research, interventional cardiology, PCI, TAVR, artificial intelligence, machine learning, operator safety, cardiovascular innovations

Navigating this challenge, SCAI’s latest guidelines advocate for alternative techniques that have demonstrated improved safety and efficacy for TAVR. One of the prominent figures involved in the creation of these guidelines, Dr. Matthew W. Sherwood, highlights the need for innovation in patient access techniques. He emphasizes that despite advancements in medical devices, there remains a gap that necessitates the development of robust methodologies to facilitate TAVR procedures for patients lacking adequate femoral access. This targeted guidance aims to enhance patient outcomes considerably, particularly among elderly or frail individuals with complex vascular conditions who may be at greater risk of complications during procedures.

Published in the Journal of the Society for Cardiovascular Angiography and Interventions (JSCAI), the expert consensus statement identifies two primary alternative access methods: transcarotid and transcaval routes. These techniques are favored over older methods like transaxillary access, which, while viable, are associated with higher risks of stroke and other complications. This key distinction underscores the guidelines’ focus on modern access strategies that are yielding better patient outcomes. In particular, the transcarotid and transcaval access points have demonstrated significant promise due to their favorable safety profiles when compared to previously established practices.

Moreover, the guidelines discourage the use of techniques such as transapical and direct aortic access, which have not kept pace with advancements in technology or patient safety considerations. By outlining these recommendations, SCAI seeks to empower practitioners with evidence-based strategies for navigating the complexities of TAVR. The growing body of observational evidence has informed these guidelines, allowing professionals to make decisions that prioritize patient safety and effective care.

In conjunction with these alternative access recommendations, the guidelines also highlight the advancements in device technology and imaging guidance that support the success of TAVR procedures. Improved imaging techniques play an invaluable role in the identification and assessment of anatomical considerations for patients, aiding clinicians in selecting the most appropriate access strategy. This intersection of technological innovation with clinical practice is paving the way for enhanced procedural success rates, leading to better overall patient care.

Dr. Paul D. Mahoney, another esteemed member of the SCAI Structural Heart Disease Council, reiterates the intention behind these guidelines: to help clinicians navigate the evolving landscape of TAVR as it transitions from an experimental procedure into a widely accepted standard of care. As the patient population needing TAVR continues to expand, it becomes increasingly critical to identify best practices that align with individual patient needs and clinical evidence. The guidelines advocate for a standardized approach that includes the utilization of experienced proctors to ensure that practitioners are well-equipped to employ alternative access techniques effectively.

The call for standardization is not merely a suggestion, but a fundamental requirement for advancing the quality of care in TAVR. By emphasizing the importance of adopting established protocols at individual practice sites, the guidelines seek to reduce variability in technique and outcomes, leading to a more streamlined approach to TAVR procedures. The focus on solidifying these practices is essential as clinicians work to navigate the challenging terrain of cardiovascular disease management.

An additional layer of complexity is introduced by the need for continued research into the efficacy and safety of alternative access techniques. The guidelines acknowledge that while substantial progress has been made, there remains an imperative for further investigation to thoroughly understand the risk-benefit profiles of various approaches. Ongoing research will not only enhance current practices but may reveal novel techniques, such as intravascular lithotripsy, which hold the potential to revolutionize the field further.

Dr. Sherwood emphasizes the importance of maintaining a commitment to research and innovation within the realm of patient care. The desire to ensure the best possible outcomes for TAVR patients fuels the ongoing exploration of alternative access methods, reaffirming the commitment of cardiovascular professionals to exceed the limitations imposed by existing practices. Such dedication to patient care is vital as the medical community strives for excellence in treatment outcomes.

As interventional cardiology forges ahead, the healthcare landscape continues to evolve, guided by evidence-based practices and patient-centered care philosophies. The SCAI’s recent consensus statement not only provides much-needed guidance for performing TAVR procedures safely and effectively but also signifies a broader trend in medicine towards rationalizing and standardizing practices. This shift underscores the critical nature of collaboration, education, and continual learning within the healthcare field as professionals work diligently to optimize treatment options for patients with cardiovascular diseases.

Overall, this consensus statement sets a new benchmark within the field of interventional cardiology. By outlining preferred access strategies and emphasizing the importance of ongoing research, the SCAI ensures that clinicians will be well-equipped to provide optimal care for patients needing TAVR. The implications for clinical practice are profound, promising safer procedures and better outcomes for some of the most vulnerable patient populations.

As this field of medicine evolves, it is imperative for healthcare providers to remain informed of the latest advancements in techniques and technology. The commitment to patient-centered care, coupled with expertise and innovation, will undoubtedly lead to a brighter future for patients with aortic stenosis seeking life-saving treatment options through TAVR.

Subject of Research:
Article Title: SCAI Expert Consensus Statement on Alternative Access for Transcatheter Aortic Valve Replacement
News Publication Date: 25-Feb-2025
Web References: DSAI Article
References:
Image Credits:

Keywords: Cardiology, TAVR, Transcatheter Aortic Valve Replacement, Vascular Diseases, Alternative Access Techniques, Cardiovascular Medicine, Expert Consensus, Patient Outcomes, Aortic Stenosis, Interventional Cardiology.

The inaugural conference held last year met with resounding success, indicating a robust interest in collaborations that drive innovation in cardiac care. The New York Valves summit explicitly focuses on disseminating transformative research and techniques essential for redefining the standards of care surrounding interventional cardiology and cardiac surgery. Attendees will explore the complexities involved in managing patients with intricate heart conditions, merging the disciplines of interventional cardiology, cardiac surgery, and cardiac imaging to optimize treatment outcomes.

An extensive lineup of live case demonstrations will be a key highlight of the summit, providing firsthand experience of cutting-edge procedural techniques. This hands-on approach enhances the learning experience, as participants observe expert practitioners navigating challenging scenarios. These sessions aim to foster a deeper understanding of both conventional and groundbreaking surgical interventions, thus empowering attendees to adopt innovative practices within their clinical settings.

Furthermore, the summit aims to address a pressing concern in structural heart care—the increasing prevalence of heart diseases necessitates an urgent exploration of novel therapeutic approaches. This will be tackled through a series of interactive debates and discussions that delve into the latest evidence-based practices. The integration of expert opinions will facilitate enriched dialogues around patient selection criteria, advanced imaging modalities, and updated procedural protocols that can substantially elevate the standard of patient care.

One of the critical aspects of the New York Valves 2025 summit is the emphasis on fostering collaborative relationships among cardiovascular specialists. With significant advancements made in the fields of transcatheter interventions and personalized treatment strategies, a multidisciplinary approach is now more vital than ever. The summit provides an avenue for interventional cardiologists, heart failure specialists, cardiac surgeons, and other stakeholders to engage and strategize on the best practices for managing patients with structural heart conditions.

As the incidence of cardiovascular diseases rises, the efficacy and accessibility of emerging therapies become paramount. The summit not only aims to enhance the technical skills of its attendees but also seeks to inspire a culture of continuous learning and adaptation. By navigating the evolving landscape of valvular heart disease management, participants can better serve their patients and improve outcomes across diverse populations.

The ongoing evolution of the field—marked by groundbreaking technological innovations—demands an educational platform where healthcare professionals can immerse themselves in the latest scientific findings. In this regard, New York Valves 2025 offers an exemplary model for addressing the intricacies of procedural advancements. Attendees will gain insights into emerging technologies that have the potential to revolutionize treatment options for conditions such as aortic stenosis and mitral regurgitation, significantly altering patient trajectories in the process.

In addition to the scientific discussions, the summit will emphasize the importance of training and best practices not only for established professionals but for the next generation of healthcare workers as well. Hands-on workshops will provide experienced insights while addressing the gaps in knowledge that often hinder effective patient management. This educational continuum is designed to ensure that all participants leave equipped with practical skills that can be directly applied to their clinical practice.

Networking opportunities abound at New York Valves 2025, allowing attendees to connect with leading experts who are at the forefront of cardiovascular innovation. Forming alliances with researchers and thought leaders will not only enhance collaborative efforts in clinical settings but also inspire new research initiatives that tackle unresolved issues in structural heart care.

The global reach of the summit further emphasizes its role in shaping the standards of heart care worldwide. Given the profound impact of cardiovascular diseases on healthcare systems globally, the CRF’s commitment to driving education and innovation is both timely and necessary. Ultimately, the summit serves as a crucial meeting point for exchanging knowledge, fostering innovation, and generating actionable insights that can be translated into practice.

As the automotive industry redefines itself with advancements in technology, so too does the field of cardiovascular medicine adapt to innovations. By embracing multidisciplinary collaboration, the New York Valves summit aspires to inspire attendees to rethink the paradigms through which structural heart diseases are understood and treated. The implications of this work extend far beyond individual patient care, promoting a collective effort to optimize cardiovascular health on a larger scale.

In summary, New York Valves 2025 represents not only a gathering of experts but also a significant step toward advancing the field of structural heart care through collaboration, research, and education. As the summit approaches, the anticipation surrounding the knowledge exchange and professional growth opportunities it offers will undoubtedly resonate throughout the healthcare community, effecting much-needed change in patient outcomes.

Subject of Research: Structural Heart Care Innovations
Article Title: New York Valves 2025: Pioneering the Future of Structural Heart Care
News Publication Date: January 24, 2025
Web References: https://nyvalves2025.crfconferences.com/
References: www.crf.org
Image Credits: Cardiovascular Research Foundation

Keywords: Structural heart care, interventional cardiology, cardiac surgery, heart disease, transcatheter interventions, personalized treatment, cardiovascular disorders, healthcare collaboration, patient outcomes, medical education.